Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

Horizon and H3 Biomedicine to Collaborate

Published: Friday, May 04, 2012
Last Updated: Friday, May 04, 2012
Bookmark and Share
H3 Biomedicine to employ Horizon’s unique gene editing technology and isogenic cell lines to validate genetically defined drug targets for development of cancer therapeutics.

Horizon Discovery Ltd (Horizon) and H3 Biomedicine Inc. have announced they have entered into a collaboration agreement to identify and validate a panel of novel cancer drug targets.

H3 Biomedicine integrates human cancer genomics with next-generation synthetic organic chemistry and tumor biology capabilities to generate a large library of novel small-molecule drugs to treat cancer.

Horizon will work with H3 Biomedicine to perform target-validation experiments identifying critical cancer genome targets whose modulation will have meaningful clinical effect.

H3 Biomedicine will carry out early target discovery through pre-clinical research, while Horizon will implement its three core drug discovery tools to run alongside and support H3 Biomedicine’s discovery biology and chemistry assets and capabilities.

The goal will be to rapidly come to definitive decisions on whether or not to progress novel targets into development. Eisai Inc., which is partnered with H3 Biomedicine, will conduct any resulting clinical trials.

Horizon’s discovery tools comprise: rAAV-mediated genome editing (GENESIS™) for precision functional genomics (endogenous gene knock-in and knock-outs); an expanding panel of 400+ X-MAN™ (Mutant And Normal) human isogenic cell lines that model specific target patient genetics and their matched normal genetic backgrounds; extensive cell-based assay development and drug profiling experience.

“The successful development of new personalized medicines depends upon well validated and characterized targets and clearly defined patient populations,” commented Markus Warmuth, President and CEO, H3 Biomedicine.

Warmuth continued, “High attrition rates in clinical trials have been impacting industry for a while. We believe that clinical success starts at target selection and validation. We have elected to work with Horizon because their tools will enable H3 Biomedicine to progress toward identifying the best possible targets for new drugs with the power to have meaningful therapeutic relevance. That may help us to increase clinical success rates and expedite the delivery of new therapies to the patients who need them.”

Darrin M Disley, CEO, Horizon, said, “Horizon and H3 Biomedicine share a common belief that systematically validating mutant genes with clear roles in cancer evolution may help yield rapidly translatable targets and drugs with greater clinical significance. We believe Horizon’s precision genome editing technology, X-MAN disease models and drug profiling assets will play an essential role in working toward achieving this goal.”

Under the terms of the agreement H3 Biomedicine will have an exclusive option to acquire ownership of all program assets and intellectual property (IP) that relates to each of the target programs, with the exception of Horizon background IP.

Horizon will retain commercial rights over any target program not optioned by H3 Biomedicine.

Horizon will receive an initial upfront investment, with additional payments as pre-clinical and clinical milestones are reached.

Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,200+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Horizon Discovery Announces Two Fresh Licensing Agreements
Horizon Discovery licenses biomanufacturing cell lines to Centre for Process Innovation (CPI) and National Institute for Bioprocessing Research and Training (NIBRT).
Tuesday, September 13, 2016
Horizon Launches New E-commerce Platform and Expands UK Headquarters
Key investment includes an integrated web-shop and Enterprise Resource Planning system to support further scale and revenue growth.
Thursday, October 29, 2015
Horizon, Swift Partner on Genomic Reference Standards
Standards to be used to support validation, consistency and accuracy of the panel.
Wednesday, October 28, 2015
Horizon In-licenses Oncology Programme from Servier
License programme with milestone payments of up to £50 million plus royalties on product sales.
Thursday, October 08, 2015
Horizon Enters Bioproduction Cell Line Licensing Agreement with LakePharma, Inc.
LakePharma to take a full commercial license for GS null CHO K1 cell line from Horizon for improved efficiency in biopharmaceutical manufacturing.
Wednesday, September 16, 2015
Horizon and Redx Sign Cancer Research Collaboration
Collaboration to progress Redx Pharma plc’s novel pan-RAF inhibitor program towards out-licensing.
Friday, September 04, 2015
Horizon Discovery Appoints Mr Grahame Cook as a Non-Executive Director
Grahame brings over 20 years’ experience to Horizon.
Thursday, May 14, 2015
Transgenomic to Incorporate Horizon's Genomic Reference Standards
Horizon to provide human genomic reference standards to assure quality and performance of Transgenomic’s Multiplexed ICE COLD-PCR kits.
Thursday, April 23, 2015
Horizon Discovery & Thermo Agreement
Horizon Discovery Group plc and Thermo Fisher Scientific sign supply and commercialization agreement, which will see Thermo market and distribute Horizon’s X-MAN cell line collection.
Monday, April 20, 2015
Horizon and Partners Awarded Up to £6.2M Funding
Horizon to receive up to £652,000 to expand bioproduction research.
Thursday, March 26, 2015
Horizon Discovery Group plc and ArcherDX Sign OEM Agreement
Horizon’s Reference Materials chosen by ArcherDX to validate its FusionPlex test for non-small cell lung cancer markers.
Tuesday, March 24, 2015
Horizon Discovery Group plc Named Business of the Year at Business Weekly Awards
Horizon joins select group of companies to receive award for a second time.
Wednesday, March 18, 2015
Horizon to Support Cancer Research UK’s Stratified Medicine Program
Horizon’s Diagnostics division to provide genetically defined, human genomic reference standards.
Friday, March 13, 2015
Horizon Discovery Group to Support Cancer Research UK’s Stratified Medicine Program
Horizon’s Diagnostics division to provide genetically defined, human genomic reference standards.
Wednesday, March 11, 2015
Horizon Discovery CEO Darrin Disley wins Entrepreneur of the Year
Darrin Disley, CEO of Horizon Discovery, wins Entrepreneur of the Year award at the Quoted Company Awards 2015.
Thursday, January 29, 2015
Scientific News
Integrated Omics Analysis
Studying multi-omics promises to give a more holistic picture of the organism and its place in its ecosystem, however despite the complexities involved those within the field are optimistic.
Unravelling the Role of Key Genes and DNA Methylation in Blood Cell Malignancies
Researchers from the University of Nebraska Medical Center have demonstrated the role of Dnmt3a in safeguarding normal haematopoiesis.
Zika Virus Infection Alters Human and Viral RNA
Researchers have discovered that Zika infections results in human and viral genetic modification.
Cell Metabolism Linked to Spread of Cancer
Scientists discover macrophage metabolism can be attuned to prevent the spread of cancer.
Agilent Presents Early Career Professor Award to Dr. Roeland Verhaak
JAX professor recognized for the development and implementation of workflows for the analysis of big-data from transcriptomics to next generation sequencing approaches.
Bacterial Genes Boost Current in Human Cells
Borrowing and tweaking bacterial genes to enhance electrical activity might treat heart, nervous system injury.
Ovarian Cancer Insight
Study showed tumours release cytokines to attract macrophages, which secrete growth factors that in turn promote tumour growth.
Questioning the Safety of Selenium to Combat Cancer
Research indicates the need for change in practice as selenium supplements cannot be recommended for preventing colorectal cancer.
Less Frequent Cervical Cancer Screening
HPV-vaccinated women may only need one screening every 5 to 10 years with screening starting later in life.
Supercomputers Could Improve Cancer Diagnostics
Researchers push the boundaries of cancer research through high-performance computing to map the human immunone.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,200+ scientific videos